This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
EV-302
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Actionable Clinical Data
Kidney Cancer
ZIRCON
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO GU 2025
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2024
ASCO GU 2024
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Upper Tract Urothelial Carcinoma
Press Releases
ASCO GU 2024 Prostate Cancer
Viewing 21-40 of 95 articles
ASCO GU 2024: ProstAct-SELECT: Safety, Tolerability, and Dosimetry of 177Lu-TLX591 with Best Standard of Care in Patients with PSMA-Expressing mCRPC
ASCO GU 2024: Real-world Treatment Sequences and Time to Discontinuation in the First-line mCRPC Setting
ASCO GU 2024: SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-tumor Efficacy of 67Cu-SAR-BisPSMA in Patients With mCRPC
ASCO GU 2024: Neoadjuvant Darolutamide Plus Androgen Deprivation Therapy for High-Risk/Very High-Risk Localized Prostate Cancer: A Multicenter, Open-Labeled, Single-Arm Phase II Trial
ASCO GU 2024: Phase 1B/2 Study of Pembrolizumab Plus Platinum/Etoposide and Platinum/Etoposide for Neuroendocrine Metastatic Prostate Cancer: Keynote-365 Cohort I
ASCO GU 2024: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing Darolutamide vs Enzalutamide Monotherapy on Serum Testosterone Levels in Patients With Castration-Sensitive Prostate Cancer After Biochemical Recurrence
ASCO GU 2024: A Systematic Review: Are the Findings of Indirect Treatment Comparisons in Metastatic Hormone-Sensitive Prostate Cancer Consistent?
ASCO GU 2024: Real-World Homologous Recombination Repair Mutation Testing Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib in the United States
ASCO GU 2024: A Phase 2 Single-Arm Study Testing SBRT, Adenosine Signaling Modulation, and Immune Checkpoint Inhibition for Men with Hormone-Sensitive Oligometastatic Prostate Cancer (SBRT-AMICO)
ASCO GU 2024: Apalutamide plus Intermittent Versus Continuous Androgen-Deprivation Therapy in Participants with Metastatic Castration-Sensitive Prostate Cancer: LIBERTAS Phase 3 Study Design
ASCO GU 2024: Salvage Radiotherapy Options for Biochemical Recurrence After Local Treatment
ASCO GU 2024: A Phase 1/2 Study of ONCT-534, a Dual-Action Androgen Receptor Inhibitor in Patients with Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2024: Apalutamide and Stereotactic Body Radiation Therapy for Low-Burden, Metastatic, Hormone-Sensitive Prostate Cancer: A Randomized Trial (PERSIAN)
ASCO GU 2024: EORTC GUCG 2238 De-Escalate: A Pragmatic Trial to Revisit Intermittent Androgen-Deprivation Therapy in Metastatic Hormone-Naïve Prostate Cancer in the Era of New AR Pathway Inhibitors
ASCO GU 2024: COMBAT: A Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPr-Expressing Metastatic Castrate-Resistant Prostate Cancer
ASCO GU 2024: Impact of Race on Outcomes to 177-Lu-PSMA-617 for mCRPC
ASCO GU 2024: Remote Delivery of Cancer Genetic Testing in Veterans with Metastatic Prostate Cancer: A Million Veteran Program Study
ASCO GU 2024: Real-Life Data on [177Lu]Lu-PSMA-617: Descriptive Analysis on the Largest mCRPC Cohort Treated in France
ASCO GU 2024: Disparities in Prostate Cancer Mortality and Clinical Trial Availability Across Vulnerable Populations
ASCO GU 2024: ASCERTAIN: An Open-Label, Randomized, Phase 1, Window-of-Opportunity Study to Investigate the Biological Effects of Saruparib (AZD5305) and Darolutamide Alone or in Combination in Men with Prostate Cancer Eligible for Radical Prostatectomy
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free